

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter and Half Year Ended 30 th September 2021


PART I

(Rs. In Lakhs) except EPS

Sl.No	Particulars	3 months ended	Previous 3	Corresponding 3	Year to Date	Corresponding	For the Previous
		(30-09-2021)	months ended	months ended	for the Period	Year to date	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From operations	2,843.92	2,125.86	1,519.96	4,969.78	3,190.21	7,121.79
II	Other Income	17.64	17.00	22.71	34.64	40.26	74.93
III	Total Income (I+II)	2,861.56	2,142.87	1,542.67	5,004.43	3,230.47	7,196.72
IV	EXPENSES						
a)	Cost of materials consumed	1,841.87	1,361.65	1,044.27	3,203.52	2,120.46	4,250.95
b)	Purchases of Stock-in-Trade	-	-	-	-	-	-
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(223.95)	(53.71)	(51.91)	(277.66)	42.25	294.60
d)	Employee benefits expense	389.88	325.99	301.51	715.87	480.88	1,198.41
e)	Finance costs	10.91	10.61	2.12	21.52	3.77	74.19
f)	Depreciation and amortization expenses	142.28	146.09	101.36	288.37	196.09	447.82
g)	Other expenses	266.41	143.54	97.46	409.95	158.00	348.07
	Total expenses (IV)	2,427.40	1,934.17	1,494.81	4,361.57	3,001.45	6,614.05
V	Profit/(loss) before exceptional items and tax (I-IV)	434.16	208.70	47.87	642.86	229.03	582.67
VI	Exceptional Items	196.53	-	-	196.53	-	-
VII	Profit/ (loss) before exceptions items and tax(V-VI)	237.63	208.70	47.87	446.33	229.03	582.67
VIII	Tax expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	237.63	208.70	47.87	446.33	229.03	582.67
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	237.63	208.70	47.87	446.33	229.03	582.67
	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	(13.06)	-	-	(13.06)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)Comprising Profit (Loss) and Other comprehensive Income for the period)	224.58	208.70	47.87	433.27	229.03	582.67
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.95	0.88	0.20	1.83	0.97	2.46
	(2) Diluted	0.95	0.88	0.20	1.83	0.97	2.46
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)						
	(1)Basic	0.95	0.88	0.20	1.83	0.97	2.46
	(2) Diluted	0.95	0.88	0.20	1.83	0.97	2.46

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee on 11.11.2021 and subsequently approved by the Board of Directors at their Meeting held on 12.11.2021
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The above figures have been regrouped and Re-arranged Wherever considered necessary
- Being the Second Quarter of the year, Figures of the Quarter ended 30th September 2021 and Year to date for this Quarter are the balancing figures of the Year to date Figures.
- Due to technical delays in the updation in line with the production process in the SAP system, the Company has not valued inventories on the basis of IND AS 2 principles. the same would be streamlined to comply with the standard by the end of Current Financial Year and the resultant impact if any would be quantified appropriately .
- The Company has provided the entire Gratuity liability as on 30th September 2021 in the books during the current period to the extent of Rs. 267.99 Lakhs, of which Rs. 196.53 Lakhs pertains to the earlier years has been shown under Exceptional Items and Rs. 13.06 Lakhs which was gain /loss on actuarial Valuation has been shown under other Comprehensive Income and the Balance of Rs. 58.40 Lakhs has been charged during the current period.
- The impact arising out of COVID-19 Pandemic on the future results of the Company will depend on developments, that are highly uncertain, including among other thing, any new information concerning the severity of the COVID-19 pandemic and any action to contain its spread or mitigate its impact whether government mandated or elected by the Company. The Company will continue to closely monitor any material changes in future economic conditions.

Place: Chennai
Date: 12.11.2021

For BAFNA PHARMACEUTICALS
LIMITED

(S. HEMALATHA)
Whole Time Director
DIN :02714329



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone Balance Sheet as on

(Rs. In Lakhs)

Particulars	Stand Alone		
	As at 30th September 2021	As at 30th September 2020	As at 31 st March 2021
	Unaudited	Unaudited	Audited
ASSETS			
Non-Current Assets			
(a) Property, Plant and Equipment	3,711.17	3,452.76	3,596.64
(b) Capital Work-in-Progress	196.72	48.83	83.13
(c) Goodwill			
(d) Other Intangible Assets			
(e) Financial Assets			
(i) Investments	-		-
(ii) Trade Receivables			
(iii) Loans			
(iv) Other financials assets			
(g) Other Non-Current Assets			
Total Non-Current Assets	3,907.89	3,501.59	3,679.77
Current Assets			
(a) Inventories	1,875.55	1,374.18	1,544.34
(b) Financial Assets			
(i) Investments			
(ii) Trade Receivables	1,870.31	1,169.19	955.95
(iii) Cash and Cash Equivalents	72.38	122.07	180.37
(iv) Bank balance other than mentioned above			
(v) Loans			
(vi) Other financials assets			-
(c) Other Current Assets	1,619.71	1,267.80	2,286.16
(d) Assets classified as held for sale			
Total Current Assets	5,437.95	3,933.24	4,966.82
Total Assets (1+2)	9,345.84	7,434.83	8,646.59
EQUITY AND LIABILITIES			
(a) Equity Capital	2,365.63	2,365.63	2,365.63
(b) Other Equity	4,131.36	2,958.03	3,311.48
(c) Equity Share Warrants			
Equity Attributable to Equity Shareholders	6,496.99	5,323.67	5,677.11
(d) Non controlling Interests	-	-	-
Total Equity	6,496.99	5,323.67	5,677.11
Liabilities			
(a) Non-Current Liabilities			
(i) Financial Liabilities			
- Borrowings	304.56	-	250.00
- Trade Payable			
- Other Financial Liabilities	227.67	354.60	278.60
(ii) Provisions			
(iii) Deferred Tax Liabilities (Net)			
(iv) Other non-current liabilities	206.53	10.00	10.00
Total Non-Current Liabilities	738.76	364.60	538.60
(b) Current Liabilities			
(i) Financial Liabilities			
- Borrowings			
- Trade Payable	1,859.67	1,471.43	1,069.16
- Dues to micro and small enterprises			
- Dues to Others			
- Other Financial Liabilities	-		1,000.00
(ii) Other Current Liabilities	250.43	275.15	361.72
(iii) Provisions			
(iv) Current Tax Liabilities (net)			
Total Current Liabilities	2,110.10	1,746.58	2,430.87
Total Liabilities			
Total Equity and Liabilities	9,345.84	7,434.83	8,646.59

For BAFNA PHARMACEUTICALS LIMITED

(S.HEMA LATHA)

Whole Time Director

DIN : 02714329

Place : Chennai

Date : 12.11.2021



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)
Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001
Standalone Cash flow Statement (Rs. In Lakhs)

Particulars	Stand Alone		
	As At 30th September 2021	As At 30th September 2020	As at 31 st March 2020
	Unaudited	Unaudited	Audited
Cash Flow from Operating Activities:			
Net Profit Before Tax and Including Exceptional Items	839.39	229.03	582.67
Adjustments for:			
Depreciation	288.37	196.09	447.82
Interest Paid	21.52	3.77	8.86
Interest Received	(3.48)		(3.95)
Sundry Balances Written Back			(28.35)
Other Income	(30.75)	(40.03)	(41.90)
Lease Rent Received	(0.41)	(0.23)	(0.74)
Exceptional items- Impact of impairment of Financial assets	(196.53)	-	
Other Comprehensive Income	(13.06)		
Operating Profit before Working Capital Changes	905.05	388.62	964.41
Adjustment For:			
[Increase]/decrease in Inventories	(331.21)	(232.94)	(403.09)
[Increase]/decrease in Trade Receivables	(914.36)	(565.71)	(352.47)
[Increase]/decrease in Short Term Loans and Advances	666.45	(272.46)	(1,290.82)
Increase/[decrease] in Trade Payables	790.51	217.29	(184.98)
Increase/[decrease] in Other Current Liabilities	(111.28)	(170.50)	(93.94)
Cash generated from Operation	1,005.15	(635.70)	(1,360.89)
Less: Tax Paid	-	-	-
Net Cash Used in Operating Activity (A)	1,005.15	(635.70)	(1,360.89)
Cash Flow from Investing Activities:			
Purchase of Fixed Assets	(228.12)	(179.57)	(609.47)
Other Income	30.75	40.03	41.90
Interest Received	3.48	-	3.95
Sundry Balances Written Back	-	-	28.35
Lease Rent received	0.41	0.23	0.74
Changes in Long Term Loans and Advances			
Change in Other Non- Current Assets			
Net Cash used in Investing Activities (B)	(193.47)	(139.30)	(534.54)
Cash Flow from Financing Activities			
Issue of Shares, Warrants & Application Activities	-	-	-
Proceeds of Investment Subsidy (State Govt Subsidy)	98.21	-	-
Changes in Long Term Borrowings	54.56	52.84	250.00
Changes in Short Term Borrowings	(1,050.93)	-	986.84
Interest Paid	(21.52)	(3.77)	(8.86)
Net Cash from Financing Activities (C)	(919.68)	49.08	1,227.98
Net Increase/ [Decrease] in Cash or Cash Equivalents [A+B+C]	(107.99)	(725.94)	(667.64)
Opening Balance of Cash & Cash Equivalents	180.37	848.01	848.01
Closing Balance of Cash & Cash Equivalents	72.38	122.07	180.37

Note :

Pursuant to Insertion of New Clause under Regulation 33, Sub-regulation (3), the company has prepared Standlone Cash Flows statement for the half Year Ended 30th September 2021. The Statement of Cash Flows for the half Year ended 30th September 2021, as reported in the statement have been approved by the Company's Board of Directors.

Place : Chennai
Date : 12.11.2021



For BAFNA PHARMACEUTICALS LIMITED

(S.HEMA LATHA)
Whole Time Director
DIN : 02714329